How to manage with telemedicine people with neuromuscular diseases?

Emanuele Spina1 · Francesca Trojsi2 · Stefano Tozza1 · Aniello Iovino1 · Rosa Iodice1 · Carla Passaniti2 · Gianmarco Abbadessa2 · Simona Bonavita2 · Letizia Leocani3,4 · Gioacchino Tedeschi2 · Fiore Manganelli1 · Luigi Lavorgna2 · on behalf of Digital Technologies, Web and Social Media Study Group of the Italian Society of Neurology (SIN)

Abstract

Introduction COVID-19 pandemic radically transformed our daily clinical practice, raising the need not to lose close contact with patients without being able to see them face-to-face. These issues are even more felt and evident in fragile patients, as those affected by neuromuscular disease. An important help came from new digital technologies that allow clinicians to remotely monitor health status and any deterioration of chronically ill patients.

Methods In this mini-review, an initiative of the “Digital Technologies, Web and Social Media Study Group” of the Italian Society of Neurology, we propose to analyze the approach to neuromuscular patients by looking over raising evidence on the main cornerstones of Telemedicine (TM): clinician-patient interaction, remote clinical assessment, remote monitoring, and digital therapeutics. In particular, we explored the strategies developed by researchers and their impact on the physical and emotional status of the patients, with particular focusing on their adherence to the program of virtual monitoring.

Results TM plays an important role in each of four stages of approach to neuromuscular disease, having demonstrated validity in keep close clinical patient interaction, clinical assessment, remote monitoring, and telerehabilitation. Nevertheless, there is no remote alternative to electrophysiological testing neither validate tools to assess disability.

Conclusion The role of TM in neuromuscular care is yet underestimated but is crucial, beyond the pandemic era. Further development of TM is advisable, through making specific apps, remotely controlled by clinicians, and making more engaging clinicians-patients interaction. Last, it is necessary to ensure adequate internet access to everyone.

Keywords Telemedicine · TeleRehabilitation · Tele-health · Neuromuscular disease · COVID-19

Introduction

The infection by the SARS-CoV-2 virus began in late 2019 in Wuhan, China, and soon spread all over the world, representing a healthy emergency for the entire world population. No country in the world has been spared from the infection, and considering its great diffusivity with an infection fatality ratio of around 1.3 % [1], healthcare systems have been highly put to the test.

Neuromuscular (NM) patients are considered “fragile patients,” at high risk to develop severe symptoms of COVID-19 infection, in particular patients affected by motor neuron disease, neuropathies with autonomic or respiratory muscle involvement, neuromuscular junction disorders, and dysimmune disease treated with immunosuppressive drugs [http://www.salute.gov.it/imgs/C_17_pubblicazioni_3014_allegato.pdf]. It is crucial in this class of patients to strictly
adhere to WHO advise for preventing disease: maintaining social distancing, wearing correct face masks, avoiding crowded places and close contact, preferring outside meetings, and providing adequate hand hygiene [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public].

On these indications, clinicians, and in particular neuromuscular specialists, tried to avoid exposing their patients to unnecessary outpatient visits. On the other hand, the health status of NM patients needs to be constantly assessed, to promptly catch any unexpected symptoms worsening and to avoid increasing anxiety or helpless feeling of these chronically ill patients.

In this frame, during 2020 and the beginning of 2021, telemedicine (TM) has experienced a huge development to maintain the provision of routine care in neurological and, more specifically, neuromuscular patients. Various approaches have been proposed for different diseases [2–7], but more in general, in the pandemic era, telemedicine provided the opportunity to maintain the patient-clinician alliance, reducing risks of outpatient evaluation for both patients and medical staff and becoming crucial in the management of neurological diseases resetting distances and pandemic obstacles.

As observed in other neurological conditions (e.g., Parkinsonism, dementia, epilepsy, headache), TM has replaced in many cases outpatient visits [2–7]. Nevertheless, its use in NM care is yet dramatically underrated with few reports about the use of telemedicine care for neuromuscular diseases affected patients [8]. Here, we propose to review the approach to neuromuscular patients by analyzing raising evidence on the main cornerstones of TM: clinician-patient interaction, remote clinical assessment, remote monitoring, and digital therapeutics.

**Clinician-patient interaction**

TM means “healing at a distance,” and, according to WHO definition, is “The delivery of health care services, where distance is a critical factor, by all health care professionals using information and communication technologies for the exchange of valid information for the diagnosis, treatment and prevention of disease and injuries, research and evaluation, and for the continuing education of health care providers, all in the interests of advancing the health of individuals and their communities,” and it is based on the following four elements:

1. Providing clinical support
2. Overcoming geographical barriers, connecting users who are not in the same physical location
3. Involving the use of various types of ICT
4. Improving health outcomes [https://www.who.int/goe/publications/goe_telemedicine_2010.pdf]

To do so, the first and most important feature of TM is to maintain close contact between clinicians and patients that, apart from the medical aspect, is crucial to provide psychological support to NM patients that are experiencing a dramatic social retirement with a sense of abandonment even on the part of the medical institution. Furthermore, TM could represent a simple tool to strengthen the doctor-patient alliance to facilitate the resumption of normal follow-ups at the end of the pandemic alert.

To facilitate clinicians-patients interactions, in the last year, various approaches have been proposed. In a little cohort (four siblings) of facioscapulohumeral dystrophy (FSHD), a team made up of neurologists, psychologists, pneumologists, and nurses, due to difficulties connected to reach referral center, try to apply a Telemedicine System based on systematic video-conferences and telemonitoring of cardiorespiratory variables. As result, the authors found a dropping in hospital admission and positive effects on mood; the very limit of this trial was the short duration, only 6 months [9]. Similar results were observed in three patients affected by various neuromuscular diseases, with a drop from 18 hospital admission in the period before TM management to 3 admissions during the TM period [10]. Moreover, underlying the importance of maintaining a strict contact in chronically ill patients, the greatest effects of TM on quality of life have been registered particularly on patients with moderate-to-severe disability, enlightening its key role in counteracting the sense of abandonment in fragile people [11].

Nevertheless, there is a lot to do under clinical aspect: a recent survey on remote consultation in Neurology daily practice showed the lowest grade of satisfaction among neuromuscular patients, probably due to feeling of needing direct clinical evaluation, and aged patients, probably due to their low familiarity with virtual devices [12]. Moreover, in many countries, authors could not ignore the issue raised by the inhomogeneous access to internet facilities of people affected by neuromuscular disease or technical issues of local institutions that have not yet provided to update their technologies.

**Remote clinical assessment**

Moving from these bases, we should keep in mind that a peculiarity of neuromuscular evaluation is the request of a close clinician-patient contact to make a diagnosis. Moreover, as in the whole Neurology, clinical evaluation plays a key role in the approach to the patient: in Charcot-Marie-Tooth patients, for example, it is difficult to estimate a clinical worsening, since the patient’s health perception does not correlate with clinical disability [13, 14]. So how to overcome these limitations?

We must separate the neuromuscular approach into two steps: the neurological examination, including strength
assessment, through evaluation of segmental strength, applying Medical Research Council (MRC, evaluating six pairs of muscles) [15]; sensory impairment evaluation (pinprick, touch, vibration sense) referred to every single nervous trunk; deep tendon reflexes (DTR) apart from classical neurological evaluation, from cranial nerves to cerebellar and gait assessment. Against the belief that in those patients an alternative to evaluation, from cranial nerves to cerebellar and gait assessment, through evaluation of segmental strength, apply to every single nervous trunk; deep tendon reflexes (DTR) apart from classical neurological evaluation, from cranial nerves to cerebellar and gait assessment, they are easy to evaluate through video assessment with an adequate caregivers how to use a pin or cotton swab to test sensitivity; as regards the remaining neurological signs to examine and considered crucial for these patients (evaluation of balance and gait, the performance of cerebellar tasks), they are easy to evaluate through video assessment with an adequate caregivers training [15, 16]. Moreover, in specific conditions, like neuromuscular junction disease (e.g., Myasthenia Gravis), the neurological evaluation must include repetitive maneuvers to test fatigability that can easily be performed virtually [17].

Another interesting study proposed the introduction of the Veteran Affairs Neuropathy Scale (VANS), a remote examination tool useful to diagnose and monitor the severity of polymyopathies with acceptable levels of sensitivity and specificity. Nevertheless, this scale needs real validation, beyond pilot study [18].

Another key feature in neuromuscular care evaluation is the assessment of the overall disability: changes in patients’ disability may be caught through easy-to-administer tools (in most cases, NM patients are cognitively intact), useful to assess functional autonomy in many NM diseases, as the Overall Neuropathy Limitations Scale (ONLS) [19] or the inflammatory Rasch-built Overall Disability Scale (i-RODS) [20]. ONLS measures the grade of disability for upper and lower limbs separately by assessing activities of daily life limited by the neurological impairment (e.g., washing hair, turning key in a lock, doing button or zips, walking with or without aid), while i-RODS consists of questionnaires about limitations in every-day life tasks (from reading magazines to doing dishes or dancing) and is used mainly to identify gross changes in health status. The changing in these scorers helps the clinician to quantify the disease worsening to address a cycle of pharmacological or physical therapies. Both these scales could be easily performed by phone interview or during telematic consult in few minutes.

However, except i-RODS scale [20], there is no validation of these approaches in routine care; nevertheless, considering the necessity to develop remote surveillance regardless of the pandemic era (e.g., patients with reduced mobility), the evolution of care in Neurology and neuromuscular care must pass from the use of alternative methods with respect to classic outpatient visits that had to remain of primary importance but to be reserved only when strictly appropriate.

Regarding clinical assessment, a very important contribution was given by a recently published analysis on 2999 telemedicine encounters in which, comparing the effectiveness of visit for each neurology sub-specialties, authors concluded against the perception that sensorimotor system examination in TM visits is more challenging in neuromuscular care, not having observed any difference in safety and quality outcomes respect to other diagnoses, as epilepsy [21].

The true limitation of a telemedicine application in neuromuscular care, which could not be addressed in an alternative way, is electrodiagnostic testing (EDX), which provides complete information on nerves, muscles, and nerve-muscle interface status. The EDX has a wide spectrum of use in NM cares, and is crucial to make the diagnosis and to monitor any deterioration and cannot be surrogated through tele-assessment [22].

Indeed, few urgencies require prompt execution of EDX testing. According to a recent review [23], clear clinical pictures that need urgent EDX are Guillain-Barré syndrome and myasthenic syndrome in which delays in obtaining antibody titers could be detrimental for patients; in other cases, as suggested also by Italian neurophysiologists [24], EDX testing should be postponed, except fast progressive cases of inflammatory neuropathies/myopathies or clinically unclear amyotrophic lateral sclerosis [23]. Furthermore, conditions that require urgency in performing EDX testing are frequently life-threatening, with the need for in-hospital management; so there is no necessity of alternative assessment as in chronic management, which remains the main target of telemedicine in neuromuscular care. Otherwise, we can suggest requesting polymerase chain reaction studies on nasopharyngeal swabs 24h in advance of the EDX study that cannot be postponed anymore.

Remote monitoring

TM has a huge potential to explore. Apart from the role of replacing ambulatory evaluations, other possible applications of telemedicine in the development of tele-health applications to remotely control in a continuous way patients. By using devices or apps (as it already happens in other neurological diseases like multiple sclerosis) [25], possibly connected to the referring tertiary neuromuscular center, patients can provide clinicians daily information about their health status. This information appears to be useful to monitor not only general condition (e.g., blood pressure, cardiac rhythm, oxygen saturation), but also ambulatory performances (e.g., walking speed, balance, or resistance performance, as in the 6-min walk test, recently proved as a reliable tool to evaluate patients’ health status changes) [26], the entity of body movements (actigraphs or accelerometers) and strength (vigorimeter), letting clinicians able to monitor by remote patients’ health status.
Table 1  Adherence and efficacy in TM clinical trial for neuromuscular care

| Authors               | Disease                      | Design                           | Tool                                                                 | Adherence                      | Outcome and efficacy                                                                 | Strength                                                                 | Limits                           |
|-----------------------|------------------------------|----------------------------------|----------------------------------------------------------------------|--------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------|---------------------------------|
| Portaro et al., 2018 [9] | FSHD                         | Open label, only treated group    | Video-conferencing, telemonitoring of cardiorespiratory variables and telerehabilitation | All patients completed the study | Dropping of hospital admission for check-up; mild improvement in mood and emotional status of all the patients | Increased autonomy and self-monitoring preventing unnecessary hospital admission | Short duration (only 6 mo)      |
| Zamarron et al., 2013 [10] | FSHD, ALS, DMD               | Open label, only treated group    | Remote monitoring of biological signals, video-conference           | All patients completed the study | Acceptable level of satisfaction, dropping of hospital admission (18 to 3 in a previous period of same duration) | Long-term monitoring (5 yr); high level of feasibility                        | No existing standard of care in telemedicine; lag in video connections, technical problems; outcome measures not specific for diseases |
| Martinez et al., 2021 [11] | Rare neuromuscular disease    | Open, treated vs control group    | Tele-assistance via skype video-conferencing in 7 wk                | All patients completed the study | Improving of quality of life in patients with moderate (both physical and psychosocial field) to severe (only psychosocial) disability degree | Design of the study, sample size, multidomain evaluation                     | Large patients cohort and longitudinal data                                 |
| Rockette-Wagner et al., 2021 [28] | Inflammatory myopathy       | Open label, observational         | Remote monitoring with wearable devices, FDA approved             | 29/44 (66%) provided valid data at baseline and follow up | Portable devices output variables had good reliability and validity for changes in the physical activity of IIM patients | Large patients cohort and longitudinal data                                  | Output variables of portable devices not yet validated; cohort heterogeneity, |
| Sobieranska et al., 2020 [29] | DMD                          | Open label, observational         | Tele rehabilitation with online workshop                         | 45 respondent out of 69 enrolled (69%), 16 (23%) participated in live workshop; 132 total visualization of online videos | Online videos are more acceptable than live sessions; motor assessment results will be presented | Limited data available                                                      | Limited data available          |
and to decide whether to program or delay new virtual or face-to-face clinical assessment. As regards general condition monitoring, in the yet cited study on four FSHD siblings, Telemedicine System provided three times a day cardiopulmonary parameters to the Control Center in case of stable disease; otherwise in case of the unstable condition, it provided 24-h 7-day information on patient health status to skilled operators at Control Centers directly in contact with a specialist in case of urgent needs [9]. However, main advances in remote monitoring have been conducted in ALS patients, in which remotely connected devices for monitoring pulmonary performance have been introduced for 10 years [27].

Regarding specific concerns in neuromuscular care, TM should include remote monitoring of muscle strength, actigraphy, and electrical impedance myography with daily transmission to the referral center, as underlined in a recent opinion on optimization of remotely conduct clinical trials in ALS (Table 1) [30]. A recent study on portable activity monitors for idiopathic inflammatory myopathies measuring average step counts/minute; peak 1-min cadence showed high compliance of patients in wearing devices (revealing a high level of patients commitment toward disease) and a very high level of concordance of these measurements with classical in-patient or ambulatory clinical evaluation. It demonstrated validity in register changes in the physical status of neuromuscular patients, with early recognition of worsening [28].

### Digital therapeutics

There are many different neuromuscular diseases with very different treatments. As regards pharmacological approaches, we can divide them into in-hospital and out-hospital treatments. Some in-hospital treatments should not be postponed or surrogated, as antisense oligonucleotide (ASO) treatment in spinal muscular atrophy (SMA), inotersen and patisiran administration for transthyretin amyloidosis (ATTRv), ASO for muscular dystrophy of Duchenne/Becker (DMD/BMD), glucosidase alfa for Pompe disease, or rituximab in chronic inflammatory demyelinating polynuropathy (CIDP) [31]. Nevertheless, some in-hospital treatments can be replaced: for example, in chronically affected dysimmune patients who need monthly IVIG, as it happens in CIDP, the clinician can switch to home-administered subcutaneous immunoglobulin formulation, with remote-video strict control of the disease course. Regarding home therapies, long-term oral steroids or immunosuppressive agents (azathioprine, methotrexate) should be continued without interruption [32, 33]. According to this approach, the survey of the Italian Association of Myology demonstrated a satisfactory level of neuromuscular care only in continuing pharmacological therapies, mostly thanks to chronic home therapy (93.3% of the pre-COVID level) [34].

The same survey depicted instead a tragic picture on a physical therapy session with a 93% of reduction; physical therapy is essential in the management of those patients, which in most cases are chronically affected and need continuous physical stimulation to optimize their residual function [34]. Most of this reduction is due to the closure of hospital clinics of rehabilitation and limiting home rehabilitation, raising a big issue in the daily management of neuromuscular patients and imposing the need to find an alternative approach for these patients because according to the guidelines of the Italian Society of Physical Medicine [http://www.simferweb.net/varie_sito_simfer_allegati/varie/lineeGuida/LINEE-GUIDA_PER_LA_RIABILITAZIONE DELLE_MALATTIE_NEUROMUSCOLARI_INFANTILI_DI-ORIGINE_GENETICA/2003-09-08_Mal_NMgenet.pdf] neuromuscular diseases need daily physical treatment. If for stroke and multiple sclerosis the role of telerehabilitation had been widely assessed [https://snlg.iss.it/wp-content/uploads/2018/05/Santilli_Vol_LineeGuida_MFR_parte-2_bis.pdf], there is no mention in the literature of telerehabilitation in NM diseases, except one recently published paper, proposing a model of telerehabilitation in DMD patients. In that study, the authors established an online program of rehabilitation based on virtual workshops, videos with exercise instructions with the participation of multidisciplinary team, and/or individual online consultations. The possibility to continue online their rehabilitation was positively received by patients and caregivers, with high level of usage [29]. By enhancing the engagement of NM patients and by developing a specific model of telerehabilitation for NM care, the goal is to improve the physical and mental health of our patients, decreasing trips to the hospital and amount of pharmacological therapies.

### Conclusion

Concluding, COVID-19 had dramatically changed our way to manage healthcare, introducing new techniques to follow up and visit patients. The role of telemedicine in neuromuscular care is yet underestimated but will be crucial, beyond the pandemic era, in avoiding useless evaluation in chronically ill patients, in managing routine care, and in identifying those patients who need urgent and direct clinical or electrophysiological assessment. Further development of TM is advisable, through making of specific apps, remotely controlled by clinicians, useful to monitor daily changes in physical performances of neuromuscular patients and through ensuring adequate internet access to everyone.

**Financial disclosures**

ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosures; ST reported no financial disclosures; AI reported no financial disclosures; ES reported no financial disclosures; FT reported no financial disclosed
no financial disclosures; RI reported no financial disclosures; CP reported no financial disclosures; GA reported no financial disclosures; SB reported no financial disclosures; LL reported no financial disclosures; FM reported no financial disclosures; GT reported no financial disclosures; FF reported no financial disclosures; LB reported no financial disclosures; RG reported no financial disclosures; JP reported no financial disclosures; CT reported no financial disclosures; RF reported no financial disclosures; JT reported no financial disclosures; WM reported no financial disclosures.

Funding Open access funding provided by Università degli Studi di Napoli Federico II within the CRUI-CARE Agreement.

Declarations

Ethical approval Authors confirm that they have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. This study did not directly involve human subjects.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. De Natale G, Ricciardi V, De Luca G et al (2020) The COVID-19 infection in Italy: a statistical study of an abnormally severe disease. J Clin Med 9(5):1564. https://doi.org/10.3390/jcm9051564
2. Iodice F, Romoli M, Giometto B et al (2021) Digital Technologies, Web and Social Media Study Group of the Italian Society of Neurology. Stroke and digital technology: a wake-up call from COVID-19 pandemic. Neurol Sci 42(3):805–809. https://doi.org/10.1007/s10072-020-04479-3 Epub 2021 Jan 12
3. Bombaci A, Abbadesa G, Troisi F, Leocani L, Bonavita S, Lavorgna L (2021) Digital Technologies, Web and Social Media Study Group of the Italian Society of Neurology. Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail. Neurol Sci 42(1):9–13. https://doi.org/10.1007/s10072-020-04783-x Epub 2020 Oct 6
4. Miele G, Straccia G, Moccia M, Leocani L, Tedeschi G, Bonavita S, Lavorgna L, on behalf of the Digital Technologies, Web and Social Media Study Group of the Italian Society of Neurology. Telemedicine in Parkinson’s disease: how to ensure patient needs and continuity of care at the time of COVID-19 pandemic. Telemed J E Health 26(12):1533–1536. https://doi.org/10.1089/tmj.2020.0184 Epub 2020 Jul 13
5. Cuffaro L, Di Lorenzo F, Bonavita S, Tedeschi G, Leocani L, Lavorgna L (2020) Dementia care and COVID-19 pandemic: a necessary digital revolution. Neurol Sci 41(8):1977–1979. https://doi.org/10.1007/s10072-020-04512-4 Epub 2020 Jun 17
6. Brigo F, Bonavita S, Leocani L, Tedeschi G, Lavorgna L (2020) Digital Technologies, Web and Social Media Study Group of the Italian Society of Neurology. Telemedicine and the challenge of epilepsy management at the time of COVID-19 pandemic. Epilepsy Behav 110:107164. https://doi.org/10.1016/j.yebeh.2020.107164 Epub 2020 May 15
7. Moccia M, Lanzillo R, Broscia Morra V et al. Digital Technologies Web and Social Media Study Group of the Italian Society of Neurology. Assessing disability and relapses in multiple sclerosis on tele-neurology. Neurol Sci. 2020 Jun;41(6):1369-1371. 10.1007/s10072-020-04470-x. Epub 2020 May 21.
8. Domingue RB, Mantese CE (2020) Aquino da Silva E, Fantini Malheiro Moraes FG, do Prado Fernandes G, Nitirini R. Telemedicine in neurology: current evidence. Arq Neuropsiquiatr 78(12):818–826. https://doi.org/10.1590/0004-282X20200131
9. Portaro S, Calabrò RS, Bramanti P (2018) Telemedicine for facio-scapulo-humeral muscular dystrophy: a multidisciplinary approach to improve quality of life and reduce hospitalization rate? Disabil Health J 11:306–309. https://doi.org/10.1016/j.dhjo.2017.09.003
10. Zammor C, Morete E, Gonzalez F (2015) Telemedicine system for the care of patients with neuromuscular disease and chronic respiratory failure. Arch Me Sci 10(5):1047–1051. https://doi.org/10.5114/amnos.2014.46223
11. Martínez O, Amayra I, Lopez-Paz J (2021) Effects of teleassistance on the quality of life of people with rare neuromuscular diseases according to their degree of disability. Front Psychol. https://doi.org/10.3389/fpsyg.2021.637413
12. McKenna MC, Al-Hinai M, Bradley D et al (2020) Patients’ experiences of remote neurology consultations during COVID-19 pandemic. Eur Neurol 83:622–625. https://doi.org/10.1159/0005111900
13. Tozza S, Bruzzese D, Piscitotta C. et al. Motor performance deterioration accelerates after 50 years of age in Charcot-Marie-Tooth type 1A patients. Eur J Neurol 2018 Fed; 25(2): 301-306. https://doi.org/10.1111/ene.13494. Epub 2017 Dec 14.
14. Padua L, Aprile I, Cavalleri T, Commodari I, Pareyson D, Quattrone A, Rizzuto N, Vita G, Tonali P, Schenone A, Italian CMT QoL Study Group (2008) Relationship between clinical examination, quality of life, disability and depression in CMT patients: Italian multicenter study. Neurol Sci 29(3):157–162. https://doi.org/10.1007/s10072-008-0928-x Epub 2008 Jul 9
15. Kleyweg RP, van der Meché FG, Schmitz PI (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain–Barré syndrome. Muscle Nerve 14(1):1103–1109
16. Saporta MA, Granit V, Lewis R, Benatar M (2020) Yes we can: a cross-sectional analysis of 2999 telemedicine encounters during the COVID-19 pandemic. Neurol Sci (2021) 42:3553–3559
17. Tozza S, Bruzzese D, Piscitotta C et al. Motor performance deterioration accelerates after 50 years of age in Charcot-Marie-Tooth type 1A patients. Eur J Neurol 2018 Fed; 25(2): 301-306. https://doi.org/10.1111/ene.13494. Epub 2017 Dec 14.
18. Padua L, Aprile I, Cavalleri T, Commodari I, Pareyson D, Quattrone A, Rizzuto N, Vita G, Tonali P, Schenone A, Italian CMT QoL Study Group (2008) Relationship between clinical examination, quality of life, disability and depression in CMT patients: Italian multicenter study. Neurol Sci 29(3):157–162. https://doi.org/10.1007/s10072-008-0928-x Epub 2008 Jul 9
19. Wilson AM, Ong MK, Saliba D, Jamal NI (2019) The Veterans Affairs Neuropsychiatry Scale: a reliable, remote, polynuropsychiatry exam. Front Neurol. https://doi.org/10.3389/fneur.2019.01050
20. Graham RC, Hughes RA (2006) A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J Neurol Neurosurg Psychiatry 77(8):973–976 (Epub 2006 Mar 30)
21. van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuijwaard K, Faber CG, Merkies ISJ (2011) Rasch-buil Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology. https://doi.org/10.1212/WNL.0b013e318208824b
22. Lipa MB, Jan JJ (2012) Electrodiagnosis in neuromuscular disease. Phys Med Rehabil Clin N Am 23(3):565–587. https://doi.org/10.1016/j.pmr.2012.06.007
23. Kassardjian CD, Desai U, Narayanaswami P (2020) Practical guidance for managing electromyography request and testing during the COVID-19 pandemic. Muscle Nerve 62:30–33. https://doi.org/10.1002/mus.26891
24. Dubbioso R, Nobile-Orazio E, Manganelli F, on behalf of SIN, SINC and ASNP et al (2020) Dealing with immune-mediated neuropathies during COVID-10 outbreak: practical recommendation from the task force of the Italian Society of Neurology (SIN), the Italian Society of Clinical Neurophysiology (SINC) and the Italian Peripheral Nerve Association (ASNP). Neurol Sci 41:1345–1348. https://doi.org/10.1007/s10072-020-04448-9
25. Silveira SL, Baird JF and Motl RW (2021) Rates, pattern and correlates of fitness tracker use among older adults with multiple sclerosis. Disabil Health J 14(1):100966. https://doi.org/10.1016/j.dhjo.2020.100966
26. Spina E, Topa A, Iodice R, Tozza S, Ruggiero L, Dubbioso R, Esposito M, Dolce P, Santoro L, Manganelli F (2019) Six-minute walk test is reliable and sensitive in detecting response to therapy in CIDP. J Neurol 266:860–865. https://doi.org/10.1007/s00415-019-09207-1
27. Lopes de Almeida JP, Pinto AC, Pereira J, Pinto S, de Carvalho M (2010) Implementation of a wireless device for real-time telemedical assistance of home-ventilated amyotrophic lateral sclerosis patients: a feasibility study. Telemed J E Health 16(8):883–8. https://doi.org/10.1089/tmj.2010.0042
28. Rockette-Wagner B, Saygin D, Moghadam-Kia S et al (2021) Reliability, validity and responsiveness of physical activity monitors in patients with inflammatory myopathy. Rheumatology (Oxford) 14:keab236. https://doi.org/10.1093/rheumatology/keab236
29. Sobierajska-Rek A, Manski L, Jablonska-Brudlo J, Sledzinska K, Ucinska A, Wierzba J (2021) Establishing a telerhabilitation program for patients with Duchenne muscular dystrophy in the COVID-19 pandemic. Wien Klin Wochenschr 133(7-8):344–350. https://doi.org/10.1007/s00508-020-01786-8 Epub 2020 Dec 21
30. Govindarajan R, Berry JD, Paganoni S, Pulley MT, Simmons Z (2020) Optimizing telemedicine to facilitate amyotrophic lateral sclerosis clinical trials. Muscle Nerve 62(3):321–326. https://doi.org/10.1002/mus.26921 Epub 2020 Jun 8
31. Costamagna G, Abati E, Bresolin N (2020) Management of patients with neuromuscular disorders at the time of the SARS-COV-2 pandemic. J Neurol 17:11–12. https://doi.org/10.1007/s00415-020-10149-2
32. Recasens BB, Rubio MA (2020) Neuromuscular diseases care in the era of COVID-19. Front Neurol 11:588929. https://doi.org/10.3389/fneur.2020.588929 eCollection 2020
33. Tseng Y, Chen T (2021) Care for patients with neuromuscular disorders in the COVID-19 pandemic era. Front Neurol. https://doi.org/10.3389/fneur.2021.607790
34. Mauri E, Abati E, Musumeci O et al (2020) Italian Association of Myology. Estimating the impact of COVID-19 pandemic on services provided by Italian Neuromuscular Centers: an Italian Association of Myology survey of the acute phase. Acta Myologica XXXIX:57–66. https://doi.org/10.36185/2532-1900-008

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.